Add BrightSurf on Google Email

Science News for January 21, 2002


MIT team tailors cell jackets to prevent cancer

Researchers used molecular scissors to alter the sugar coats of cancer cells, promoting tumor growth with one fragment and inhibiting it with another. This discovery could lead to targeted cancer treatments by exploiting the biological balancing act between different sugar fragments and signaling molecules.

SourceMassachusetts Institute of Technology·JournalProceedings of the National Academy of Sciences·DateJan 21, 2002

Mortality rates in Canadian neonatal ICUs

A Canadian study analyzed 19,265 infant deaths in 17 NICUs between 1996 and 1997, finding that common causes of death were birth at a different hospital, congenital anomalies, infection, and hypoxic-ischemic encephalopathy. The risk-adjusted mortality rates varied significantly among hospitals.

SourceCanadian Medical Association Journal·JournalCanadian Medical Association Journal·DateJan 21, 2002

Reactive oxygen generated by Nox1 enzyme triggers angiogenesis

Researchers discovered that Nox1 enzyme generates reactive oxygen molecules that trigger angiogenesis and tumor growth. Inhibiting Nox1 activity or reducing hydrogen peroxide levels may decrease cancer cell growth and increase sensitivity to chemotherapy.

SourceEmory University Health Sciences Center·JournalProceedings of the National Academy of Sciences·DateJan 21, 2002
Rigol DP832 Triple-Output Bench Power Supply

Rigol DP832 Triple-Output Bench Power Supply powers sensors, microcontrollers, and test circuits with programmable rails and stable outputs.

Food, mood and behaviour

The article reviews the possible psychopharmacologic effect of several nutrients on mood and behaviour. Key findings include the potential mild antidepressant effects of SAMe, folic acid, and tryptophan, as well as the relation between carbohydrate consumption and sedation.

SourceCanadian Medical Association Journal·JournalCanadian Medical Association Journal·DateJan 21, 2002

Scientists report 'one-two' punch against breast cancer

Researchers at Vanderbilt University Medical Center found that combining Herceptin with Iressa reduces tumor cell death and tumor size in HER2-overexpressing breast cancers. The clinical trial will enroll 150 patients and aims to shrink tumors with minimal side effects.

SourceVanderbilt University Medical Center·JournalCancer Research·DateJan 21, 2002